Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Br J Obstet Gynaecol1
Search Results
Sort by
- Bookedited by Charles L. Edelstein.Contents:
Chapter 1: Characteristics of an Ideal Biomarker of Kidney Diseases / M.R Bennett aand P. Devarajan
Chapter 2: Statistical Considerations in Analysis and Interpretation of Biomarker Studies / C.R. Parikh and H. Theissen Philbrook
Chapter 3: The Role of Metabolomics in the Study of Kidney Diseases and in the Development of Diagnostic Tools / U. Christians, J. Klawitter, J. Klepacki and J. Klawitter
Chapter 4: The Role of Proteomics in the Study of Kidney Diseases and in the Development of Diagnostic Tools / U. Christians, J. Klawitter, J. Klepacki and J. Klawitter
Chapter 5: Cystatin C as a Multifaceted Biomarker in Kidney Disease and Its Role in Defining "Shrunken Pore Syndrome" / A. Grubb
Chapter 6: Biomarkers in Acute Kidney Injury / C.L. Edelstein
Chapter 7: Biomarkers of Extra-Renal Complications of AKI / S. Faubel
Chapter 8: Biomarkers in Kidney Transplantation / S. Jain and A. Jani
Chapter 9: Biomarkers of Renal Cancer / N.S. Vasudev and R.E. Banks
Chapter 10: Proteomics and Advancements in Urinary Biomarkers of Diabetics Kidney Disease / M.L. Merchant and J.B. Klein
Chapter 11: Biomarkers of Cardiovascular Risk in Chronic Kidney Disease / Z.H. Endre and R.J. Walker
Chapter 12: Diagnostic and Prognostic Biomarkers in Autosomal Dominant Polycystic Kidney Disease / G. Fick-Brosnahan and B.Y. Reed
Chapter 13: Biomarkers in Glomerular Disease / J.M. Arthur, E. Elnagar and N. Karakala
Chapter 14: Biomarkers in Preeclampsia / S.A. Karamanchi.Digital Access ClinicalKey 2017 - ArticleRedman CW, Beilin LJ, Bonnar J.Br J Obstet Gynaecol. 1977 Jun;84(6):419-26.A total of 242 women with moderate hypertension in pregnancy completed a controlled trial of methyldopa (Aldomet). The hypotensive effect of methyldopa was similar to its action in non-pregnant individuals and greatly reduced the frequency of severe hypertension occurring antenatally and in labour. As pregnancy advanced, an increasing daily dose of methyldopa was needed and there was a greater use of additional hypotensive therapy. Seventeen (14-5 per cent) women assigned to methyldopa had to be transferred to another drug or had to stop treatment completely because of minor side effects, of which the commonest were lack of energy and dizziness. No serious side effects were encountered. Nine per cent of the untreated women developed severe hypertension which required treatment later in their pregnancies. Six weeks after delivery, nearly all the patients were able to stop treatment.